Pfizer 2014 Annual Report Download - page 40

Download and view the complete annual report

Please find page 40 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 40
ANNUAL REVIEW 2014
FOCUSING ON UNMET NEEDS
We focus our efforts in core areas where we believe Pzer is best
positioned to bring unique, needed therapies to patients. These core
areas include immunology and inammation, cardiovascular and
metabolic disease, oncology, vaccines, neuroscience and pain, rare
diseases, and biosimilars.
Collaborating in new and dynamic ways with other innovators across
the health landscape is key to our R&D approach. Our partners
include academic scientists, patient foundations, governments, other
biopharmaceutical companies, and treating physicians — expanding
the R&D ecosystem to better serve both patients’ needs and
our business.
Today our Phase 1 to registration pipeline is composed of more than
80 innovative therapies, including potentially rst-in-class vaccines
against two deadly hospital-acquired infections, new potential
antibodies for lupus and high cholesterol, and the next generation
of targeted potential therapies for cancer. We are also building upon
a heritage of developing safe and effective biologic medicines to
develop high quality biosimilars that may broaden patient access with
lower-cost alternative biologic therapies.
Our Science > Research and Development
RESEARCH AND DEVELOPMENT
“It is extremely motivating and a privilege
to come to work every day to advance a
drug candidate that has the potential of
dramatically improving patient lives by
slowing the progression of kidney disease
and delaying or preventing onset of dialysis.”
“Directed innovation is at the core of all of
our successes. In fact, the very premise of
starting the D1 program at Pzer was the
belief that we could innovate and succeed
on a difcult mechanism where many others
had failed, and thereby potentially help
patients with Parkinson’s disease live a
better life.”
VALERIE CLERIN
PROJECT LEAD
PDE5 INHIBITOR DIABETIC
NEPHROPATHY PROGRAM
DAVID GRAY
NEUROSCIENCE
RESEARCH UNIT
PROJECT LEAD FOR
THE D1 PARTIAL
AGONIST PROGRAM